Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review)
Neurol 66:968-975, Suchowersky,O.,et al, 2006
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection
Neurol 96:664-676, Martino, D.,et al, 2021
Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders
Neurol 92:896-906, Pringsheim, T.,et al, 2019
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 89:88-100, McKeith, I.G.,et al, 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis
JNNP 86:135-143, Wang, H.F.,et al, 2015
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Evidence-based Guideline: Treatment of Parenchymal Neurocysticercosis
Neurol 80:1424-1429, Baird, R.,et al, 2013
Evidence-based Guideline: Antiepileptic Drug Selection for People with HIV/AIDS
Neurol 78:139-145, Birbeck,G.L.,et al, 2012
Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy
JAMA 307:922-930, Engel, J.,et al, 2012
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010
Second Consensus Statement on the Diagnosis of Multiple System Atrophy
Neurol 71:670-676, Gilman,S.,et al., 2008
Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
Neurol 68:1249-1250,1245, Liow,K.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Status Epilepticus: An Evidence Based Guide
BMJ 331:673-677, Walker,M., 2005
Efficacy and Tolerability for the New Antiepileptic Drugs I: Treatment of New Onset Epilepsy
Neurol 62:1252-1260, French,J.A.,et al, 2004
Efficacy and Tolerability of the New Antiepleptic Drugs II: Treatment of Refractory Epilepsy
Neurol 62:1261-1273, French,J.A.,et al, 2004
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Safety and Efficacy of Ergotamine Tartrate & Dihydroergotamine in the Trmt of Migraine & Status Migrainosus
Neurol 45:577-584, Silberstein,S.D.,et al, 1995
Practice Parameter:Appropriate Use of Ergotamine Tartrate & Dihydroergotamine in the Trmt of Migraine & Status Migrainosus
Neurol 45:585-587, , 1995
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994
Practice Parameters:Initial Therapy of Parkinson's Disease
Report of the Quality Standards Subcommittee of AAN, Neurol 43:1296-12971993., , 1993